ClinicalTrials.gg
CompletedNCT01793480EQUIMETH2Updated Oct 31, 2024

Evaluation of the Efficacy and Safety of Two Methadone Titration Methods for the Treatment of Cancer-related Pain With Inadequate Pain Relief or Intolerable Side Effects When Treated With Level 3 Opioids.

A Phase 3 interventional study of Methadone in Pain Related to Cancer, sponsored by RECORDATI GROUP. Completed at 16 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-10-31.

Sponsored by RECORDATI GROUP · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Registered 1 year 1 month after the study started (first participant enrolled Jan 2012, registered Feb 2013).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
146
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 29 studies testing methadone in Pain — 3 open to participants now, 3 under way, none of them phase 3. Methadone · Pain.

Enrollment
2nd of 29
146 · median 40
Started
2012
the only one that year
Phase 3
3 of 29
none open now
Registered
16th of 29
by date

Among the 29 studies testing methadone in Pain, this one is the 2nd largest by enrollment, is the only one that started in 2012, is one of 3 in phase 3, and was the 16th registered.

Pain

10,069 studies on the registry are indexed under Pain; 1,650 are open to participants now.

Browse Pain studies →

Open to participants now

3 of the 29 studies testing methadone in Pain are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About methadone

Methadone: first FDA approval 1947 (DOLOPHINE HYDROCHLORIDE). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 927 Pain studies recruiting now, 382 (41%) set no upper age limit and 434 (47%) stop at 75 or younger; 146 take children under 18; 221 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 29 studies testing methadone in Pain, or all of them as a file.
02

Study summary

This is a multicentric, randomized, open-label, phase IIIb national study, to evaluate the clinical effects (success/failure) of methadone for the treatment of cancer-related-pain in patients with inadequate pain relief or intolerable side effects when treated with level 3 opioid.

Principal objective is to compare the clinical effects (success/failure) of two methods of methadone titration in patients with cancer-related pain inadequately relieved or with intolerable side effects after treatment with level 3 opioid.

Secondary objectives are : Overall safety of methadone during the study, to describe the patients' characteristics, to describe the effects of methadone on pain relief, to describe the methadone administration, to evaluate patient's quality of life, to evaluate the prescriber's opinion regarding the handling of methadone initiation.

Read the detailed description

The randomisation (1:1) will consider the two titration methadone switching methods:

  • Group A: patient-controlled dose of methadone with no overlapping with the previous opioid treatment
  • Group B: fixed-dose of methadone with overlapping with the previous opioid treatment

Study Description:

Screening visit (Visit 1) within 48 hours before the inclusion Inclusion visit (Visit2) and randomisation on Day 1 Visit 3 from Day 2 to Day 7 (hospitalisation for all patients). Four follow-up visits on Day 14 (Visit 4), Day 21(Visit 5), Day 28 (Visit 6), Day 42 (Visit 7) End of study visit on Day 56 Follow-up phone contact on Day 84.

03

Conditions studied

  • Pain Related to Cancer

Browse trials for

Keywords

  • Methadone in cancer pain
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult patient of at least 18 years of age
  • Patient suffering from cancer disease, undergoing chemotherapy treatment or not, hospitalised or requiring hospitalisation
  • Patient presenting nociceptive or mixed pains inadequately relieved with level 3 opioids (morphine, oxycodone, transdermal fentanyl, hydromorphone) with a numeric pain scale score ≥5 evidence-based or presenting intolerable side effects with level 3 opioids
  • Patient undergoing level 3 opioid treatment (morphine sulphate or morphine chlorhydrate or fentanyl or oxycodone or hydromorphone)
  • Patient presenting a good understanding of the study objectives and able to give his/her written consent
  • Patient able to communicate with the investigator or his representative
  • Patient available during the whole course of the study and agreeing the study requirements
  • Patient with Social Insurance
  • Patient having received patient's information form, orally informed and having signed the consent form

Exclusion criteria

Exclusion Criteria:

  • Patient in terminal cancer disease ( less than 2 months) according to investigator's judgement
  • Patient treated with a medication that may result in an interaction with methadone, such as: antiarrythmic treatments (Ia or III), erythromycin, spiramycin, intravenous vincamin
  • Patient receiving opioid treatment for any other reason than pain
  • Patient unable to swallow the study treatment
  • Patient presenting to the use of methadone
  • Patient having a decompensated respiratory failure or a severe hepatic disease
  • Patient having a known to methadone
  • Patient presenting prolongation on results
  • Patient receiving a concomitant treatment with a morphine-type agonist-antagonist medication (pentazocine, buprenorphine, nalbuphine) or with sultopride, or with morphinic antagonist (naltrexone)
  • Patient treated by analgesic radiotherapy within 15 days before inclusion
  • Patient participating or having participated in another clinical trial with a new therapy within one month before inclusion
  • Patient with a history of substance abuse
  • For woman with : pregnancy or breastfeeding.
  • Forfeiture of freedom or under guardianship
  • Past history of suicidal attempts
  • Patient likely not to respect the study conditions and/or study discontinuation criteria according to investigator's judgement
  • Patient presenting any other medical condition or illness or abnormal findings on the physical examination at screening that, in the opinion of the Investigator, make the patient unsuitable for the study or put the patient at additional risk.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
146 participants (actual)

Study arms

  • Experimental
    patient-controlled dose of methadone

    The titration will be done on the patient's request (patient-controlled dose of methadone), with no overlapping with the previous opioid treatment, under the investigator's supervision.

    Drug: Methadone

  • Experimental
    fixed-dose of methadone

    The titration will be done with fixed-dose of methadone, on a progressive switch with overlapping with the previous opioid treatment, to avoid withdrawal syndrome when the opioid is discontinued.

    Drug: Methadone

Interventions

06

What researchers measure

Primary outcomes

  1. Binary main criterion based on success/failure rate related to methadone switch on Day 4.

    The success is defined as the adequate pain relief on Day 4 and no occurrence of overdose between Day 1 and Day 4. All unmet definition of success will be considered as a failure. The adequate pain relief is defined as the composite criterion: * Decrease of at least 2 points on the pain numeric scale from 0 (no pain) to 10 (unacceptable pain) evaluated on Day 4 when compared to the pain numeric scale score at baseline, * And a pain numeric scale score \<5 during two consecutive days (between Day 1 and Day 4)

    Time frame: Day 4

07

Study locations

16 sites
  • Investigational Site 10
    Amiens, France
  • Investigational Site 06
    Bayonne, France
  • Investigational Site 13
    Caen, France
  • Investigational Site 03
    GAP, France
  • Investigational Site 11
    Le Chesnay, France
  • Investigational Site 07
    Lille, France
  • Investigational Site 16
    Lyon, France
  • Investigational Site 12
    Nice, France
  • Investigational Site 14
    Paris, France
  • Investigational Site 02
    Pierre Benite, France
  • Investigational Site 05
    Reims, France
  • Investigational site 08
    Strasbourg, France
  • Investigational Site 17
    Suresnes, France
  • Investigational Site 01
    Tarbes, France
  • Investigational Site 04
    Toulouse, France
  • Investigational Site 15
    Villejuif, France
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2012 to primary completion in May 2014, 28 months.

Of 105 industry-sponsored phase 3 interventional studies under Pain, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 23. This study's 28 months is above that.

Counting every sponsor, half of 216 studies reached it within 18 months; a quarter within 9 and three quarters within 38.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 14, 2013
First posted
Feb 15, 2013
StartActual
Jan 5, 2012
Primary completionActual
May 6, 2014
CompletionActual
Aug 31, 2014
Last update
Oct 31, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 31, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01793480
Lead sponsor
RECORDATI GROUP
Responsible party
Sponsor
First posted
Feb 15, 2013
Start date
Jan 5, 2012
Primary completion
May 6, 2014
Completion
Aug 31, 2014
Last update
Oct 31, 2024

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Methadone

Start the discussion